Director / PDMR Shareholding

 18th Jul 2016

EKF Diagnostics Holdings plc

(“EKF” or the “Company”)


Notification of transactions by Persons Discharging Managerial Responsibilities and persons closely associated with them.


EKF Diagnostics Holdings plc (AIM: EKF) announces that on 18 July 2016, the Company was notified that Harwood Capital LLP ("Harwood") acquired 9,000,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.

Following the above transaction, which was completed on 15 July 2016 at a price of 14.89 pence per share, NAIT's interest is now in 87,100,000 Ordinary Shares, representing 18.76% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.

The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 127,100,000 Ordinary Shares, representing 27.38% of the Company's issued share capital.

EKF Diagnostics Holdings plc
Julian Baines, CEO
Richard Evans, Finance Director and COO
00 44 29 2071 0570
 
Panmure Gordon (UK) Limited
Peter Steel
Paul Fincham
00 44 20 7886 2500

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

00 44 20 7933 8780 or ekf@walbrookpr.com
00 44 7980 541 893
00 44 7584 391 303

 

 

This notification is made in accordance with the requirements of the EU Market Abuse Regulation. Further details:

 Initial notification / amendment: Initial

Ordinary Shares Identification Code: ISIN GB0031509804

Aggregated information: N/A

Place of the transaction: London Stock Exchange, AIM (XLON)